Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2341659 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CYP1A2BCHEF2PRSS1 | |
| SCHEMBL2364197 | 0.84 | BCHE (0.62) | BCHESLC6A2SLC6A3CNR1CNR2 | |
| SCHEMBL11834924 | 0.73 | CCR1 (0.47) | ALDH1A1CYP1A2NPY2RGAAKDM4E | |
| SCHEMBL1177971 | 0.73 | ALDH1A1 (0.68) | ALDH1A1CYP1A2GAAKDM4ELMNA | |
| SCHEMBL1046242 | 0.73 | F10 (0.47) | ALDH1A1BCHEF2PRSS1KDM4E | |
| SCHEMBL11857079 | 0.73 | ALDH1A1 (0.46) | ALDH1A1CYP1A2NPY2RGAAKDM4E | |
| SCHEMBL11841818 | 0.71 | CYP1A2 (0.50) | ALDH1A1CYP1A2NPY2R | |
| SCHEMBL14060543 | 0.70 | ALDH1A1 (0.69) | ALDH1A1CYP1A2GAAKDM4ELMNA | |
| SCHEMBL7759530 | 0.70 | ALDH1A1 (0.64) | ALDH1A1CYP1A2GAAKDM4ELMNA | |
| SCHEMBL639563 | 0.70 | ALDH1A1 (0.64) | ALDH1A1CYP1A2GAAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224163-B1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | claimed |
| US-6548522-B1 | N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | claimed |
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | claimed |
| EP-1224163-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027070-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | claimed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | YALE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1224163-B1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6548522-B1 | N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| EP-1224163-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027070-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN3, KCNN4, KCNMA1 | ALDH1A1 4653/4885CYP1A2 4644/4885BCHE 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.